SEMPER PARATUS ACQU -CW26 (TVGNW) Stock News

USA - Nasdaq - NASDAQ:TVGNW -

0.045 USD

+0 (+10.02%)

Last: 11/28/2025, 8:04:13 PM

Technical Analysis

TVGNW Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

15 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

24 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

24 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

26 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

26 days ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

a month ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

2 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

3 months ago - By: Tevogen Bio Inc - Mentions: TVGN

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum